Single‐chain Fvs

Single‐chain Fvs (sFvs) are recombinant antibody fragments consisting of only the variable light chain (VL) and variable heavy chain (VH) domains covalently connected to one another by a polypeptide linker. Due to their small size. sFvs have rapid pharmacokinetics and tumor penetration in vivo. Single‐chain Fvs also show a concentration‐dependent tendency to oligomerize, Bivalent sFvs are formed when the variable domains of a sFv disassociate from one another and reassociate with the variable domains of a second sFv, Similar rearrangement and reassociation of variable domains from different sFvs can result in the formation of trimers or higher multimeric oligomers. Each Fv in a bivalent or multivalent Fv is composed of the VL domain from one sFv and the VH domain from a second sFv. Modifying linker length or the inclusion of antigen may stabilize the VL/VH interface against rearrangement such that specific multimene or monomeric forms of sFvs may be isolated. Nuclear magnetic resonance studies have shown that McPC603‐derived Fv and sFvs have similar structures, and that the sFv linker is a rapidly moving, highly flexible peptide with a random coil‐like structure. In X‐ray crystallographic investigations of three different sFvs, linkers have also been found to be disordered. Indirect evidence suggests that a monomeric sFv has been crystallized in one case, and dimeric sFvs in the other two.—Raag, R., Whitlow, M. Single‐chain Fvs. FASEB J. 9, 73‐80 (1995)

[1]  I. Pastan,et al.  A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. Friedman,et al.  Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. , 1993, Journal of immunology.

[3]  I. Pastan,et al.  In vitro and in vivo activity of a recombinant toxin, OLX-209, which targets the erbB-2 oncoprotein. , 1994, Advances in enzyme regulation.

[4]  K. D. Hardman,et al.  An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. , 1993, Protein engineering.

[5]  R. Webster,et al.  Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. , 1994, European journal of biochemistry.

[6]  M. Whitlow,et al.  Single-chain Fv proteins and their fusion proteins , 1991 .

[7]  R. Lerner,et al.  Antibody remodeling: a general solution to the design of a metal-coordination site in an antibody binding pocket. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  T. Holak,et al.  Structural and dynamic properties of the Fv fragment and the single-chain Fv fragment of an antibody in solution investigated by heteronuclear three-dimensional NMR spectroscopy. , 1994, Biochemistry.

[9]  T. Poulos,et al.  The engineering of binding affinity at metal ion binding sites for the stabilization of proteins: subtilisin as a test case. , 1988, Biochemistry.

[10]  S. Schuster,et al.  Monoclonal antibodies specific for mercuric ions. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Brisson,et al.  Solution structure of a trisaccharide-antibody complex: comparison of NMR measurements with a crystal structure. , 1994, Biochemistry.

[12]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[13]  Y. Satow,et al.  Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. , 1985, Journal of molecular biology.

[14]  T. Yokota,et al.  Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. , 1993, Cancer research.

[15]  T. Holak,et al.  Characterization of the linker peptide of the single‐chain Fv fragment of an antibody by NMR spectroscopy , 1993, FEBS letters.

[16]  T. Yokota,et al.  Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. , 1992, Cancer research.

[17]  R. Webster,et al.  Recombinant antineuraminidase single chain antibody: Expression, characterization, and crystallization in complex with antigen , 1993, Proteins.

[18]  M. Whitlow,et al.  Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. , 1994, Protein engineering.

[19]  R. Bruccoleri,et al.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Huston,et al.  Medical applications of single-chain antibodies. , 1993, International reviews of immunology.

[21]  P. Bryan,et al.  Large increases in general stability for subtilisin BPN' through incremental changes in the free energy of unfolding. , 1989, Biochemistry.

[22]  A. Plückthun,et al.  Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. , 1988, Science.

[23]  T. Bhat,et al.  Crystallographic refinement of the three-dimensional structure of the FabD1.3-lysozyme complex at 2.5-A resolution. , 1991, The Journal of biological chemistry.

[24]  E. Voss,et al.  Construction, expression, and activity of a bivalent bispecific single-chain antibody. , 1994, The Journal of biological chemistry.

[25]  I. Pastan,et al.  A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. , 1992, Analytical biochemistry.

[26]  L. Presta,et al.  X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. , 1993, Journal of molecular biology.

[27]  R. Glockshuber,et al.  A comparison of strategies to stabilize immunoglobulin Fv-fragments. , 1990, Biochemistry.

[28]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Chen,et al.  Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[31]  R. Raag,et al.  Crystallization of single-chain Fv proteins. , 1993, Journal of molecular biology.

[32]  R. Gibbs,et al.  Construction and characterization of a single-chain catalytic antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Y. Li,et al.  Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Lawson,et al.  Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. , 1994, Protein engineering.

[35]  G. Air,et al.  Three-dimensional structures of influenza virus neuraminidase-antibody complexes. , 1989, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[36]  R K Jain,et al.  Barriers to drug delivery in solid tumors. , 1994, Scientific American.

[37]  David I. Stuart,et al.  Crystal structure at 2.8 Å resolution of a soluble form of the cell adhesion molecule CD2 , 1992, Nature.

[38]  T. Teeri,et al.  An active single-chain antibody containing a cellulase linker domain is secreted by Escherichia coli. , 1991, Protein engineering.

[39]  R. Lerner,et al.  Engineering metal coordination sites into the antibody light chain , 1993 .

[40]  G. Winter,et al.  Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. , 1992, Journal of immunology.

[41]  E. Haber,et al.  Protein engineering of single-chain Fv analogs and fusion proteins. , 1991, Methods in enzymology.

[42]  P. Hudson,et al.  Recombinant single-chain antibody peptide conjugates expressed in Escherichia coli for the rapid diagnosis of HIV. , 1994, Journal of immunological methods.

[43]  K. D. Hardman,et al.  Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli. , 1991, Biochemistry.